drugset / Trial / NCT04983732
A Bioavailability Study of FL-101 in Healthy Male and Female Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
This will be a single-center, randomized, open-label, single dose, parallel study to assess the absolute bioavailability of FL-101 when administered via the subcutaneous (SC) and intravenous (IV) routes.
Timeline
- Start
- 2021-09-11
- Primary completion
- 2022-05-05
- Completion
- 2022-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FL-101 | Unknown | 150 mg | Intravenous |
Indications
No indication recorded.